Palisade Bio, Inc. PALI · Stock Open Palisade Bio, Inc. in new tab
Palisade Bio, Inc. Analysis (PALI)
Is Palisade Bio, Inc. a good investment? Palisade Bio, Inc. (PALI) is currently trading at 1.59 USD. Market analysts have a consensus price target of 10.22 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 2.62. This relatively low multiple may signal that Palisade Bio, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Palisade Bio, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.28.
Investor FAQ
Does Palisade Bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Palisade Bio, Inc.?
Palisade Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of 0.65.
Company Profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 9, 2017 | 0.08 |
| July 18, 2019 | 1:20 |
| April 28, 2021 | 0.17 |
| Nov. 16, 2022 | 1:50 |
| April 8, 2024 | 0.07 |
Community Discussion